WallStSmart

Novartis AG ADR (NVS)vsYD Bio Ltd (YDES)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 4628642% more annual revenue ($57.36B vs $1.24M). YDES leads profitability with a 24.7% profit margin vs 17.5%. NVS earns a higher WallStSmart Score of 48/100 (D+).

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

YDES

Avoid

32

out of 100

Grade: F

Growth: 6.3Profit: 3.5Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -2.29
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-67.6%)

Margin of Safety

-67.6%

Fair Value

$95.76

Current Price

$160.50

$64.74 premium

UndervaluedFair: $95.76Overvalued

Intrinsic value data unavailable for YDES.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

YDES3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
314.9%10/10

Revenue surging 314.9% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Profit MarginProfitability
24.7%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

YDES4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$422.86M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Price/BookValuation
81.3x2/10

Trading at 81.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bull Case : YDES

The strongest argument for YDES centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at -382.1%. Revenue growth of 314.9% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Bear Case : YDES

The primary concerns for YDES are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

NVS profiles as a value stock while YDES is a growth play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.45 — expect wider price swings.

YDES is growing revenue faster at 314.9% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 32/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

YD Bio Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.

Want to dig deeper into these stocks?